SA
Stefan Karl Christian Alig
Also known as: Stefan Alig, Stefan K. Alig, Stefan K.C. Alig
Research areas: Medicine · Pathology and Forensic Medicine · Lymphoma Diagnosis and Treatment · Chronic Lymphocytic Leukemia Research · Cancer Genomics and Diagnostics
0000-0001-6825-702X
Employment
Employment history is unavailable.
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (48)
- Clonal hematopoiesis and cytopenias following CAR19 therapy Save
- A machine learning–derived sarcopenia index is associated with survival and nonrelapse mortality in DLBCL Save
- Gastric and rectal administration of encorafenib with targeted chemotherapy against BRAF V600E–mutant rectal cancer with bowel obstruction Save
- Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma Save
- CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias Save
- Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma Save
- The effect of ibrutinib on the myeloid cell compartment in CNS lymphoma Save
- Evolving molecular classification of aggressive B‐cell lymphoma Save
- Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials Save
- FISHing for clarity in double-hit lymphomas Save
- Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials Save
- Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling Save
- Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomas. Save
- Outcome prediction by interim positron emission tomography and IgM monoclonal gammopathy in diffuse large B-cell lymphoma. Save
- Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas Save
- Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma. Save
- Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Save
- Circulating Tumor DNA in Untreated Classical Hodgkin Lymphoma Patients Treated with Pembrolizumab and Chemotherapy: Dynamic Response Assessment and Correlation with Baseline Metabolic Tumor Volume Save
- Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy Save
- Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas Save